Company Description
Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe.
The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders.
The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia.
In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners.
Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
| Country | Ireland |
| Founded | 1992 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 398 |
| CEO | John Gillard |
Contact Details
Address: Ida Business Park, Bray, Co Wicklow, Ireland Dublin Ireland, L2 18 Ireland | |
| Phone | 01135312955111 |
| Website | trinitybiotech.com |
Stock Details
| Ticker Symbol | TRIB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000888721 |
| CUSIP Number | 896438306 |
| ISIN Number | US8964385046 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| John Gillard | President, Chief Executive Officer, Company Secretary and Director |
| Ronan O'Caoimh | Founder and Director |
| Dr. James Walsh Ph.D. | Executive Director of Business Development and Executive Director |
| Des Fitzgerald | Interim Chief Financial Officer |
| Simon Dunne | Chief Accounting Officer |
| Dr. Gary Keating Ph.D. | Chief Technology Officer |
| Eibhlin Kelly | Chief Information Officer |
| Colm Molloy | Group Director of Human Resources and Culture |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 5, 2024 | 6-K | Report of foreign issuer |
| Feb 20, 2024 | 6-K | Report of foreign issuer |
| Feb 20, 2024 | 6-K | Report of foreign issuer |
| Feb 15, 2024 | 424B3 | Prospectus |
| Feb 9, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Feb 1, 2024 | 6-K | Report of foreign issuer |
| Feb 1, 2024 | 6-K | Report of foreign issuer |
| Jan 2, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jan 2, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jan 2, 2024 | 6-K | Report of foreign issuer |